First Ascent Biomedical’s New Study Shows Functional Precision Medicine Platform Identifies Effective Treatments for 83 Percent of Children with Difficult-to-Treat Cancers
First Ascent Biomedical announced today results from a prospective clinical study conducted in partnership with Florida International University (FIU) using a unique and groundbreaking functional precision medicine (FPM) platform.
- First Ascent Biomedical announced today results from a prospective clinical study conducted in partnership with Florida International University (FIU) using a unique and groundbreaking functional precision medicine (FPM) platform.
- The study identified specific and effective therapeutic options for 83% of study participants with pediatric relapsed or treatment-resistant cancers.
- “After a decade of research, this study validates using FPM data to inform the next line of therapy for children who have exhausted standard-of-care options.
- First Ascent Biomedical’s Functional Medicine Platform (FPM) is a first-in-kind AI-driven drug prediction platform that integrates DNA/RNA sequencing, mutation analysis, and drug sensitivity testing of cancer cells.